Global Non-interventional Heart Failure Disease Registry

NCT ID: NCT02595814

Last Updated: 2018-11-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

18805 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-23

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients at least 18 years old, or older for those countries where the adult age is above 18 years of age, hospitalized with a primary diagnosis of acute heart failure.

Exclusion Criteria

1-Concomitant participation in any/a clinical trial with any investigational treatment (for any sponsor).

2\. Use of investigational drugs within 5 half-lives of enrollment, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novartis Investigative Site

San Diego, California, United States

Site Status

Novartis Investigative Site

San Francisco, California, United States

Site Status

Novartis Investigative Site

Chicago, Illinois, United States

Site Status

Novartis Investigative Site

Indianapolis, Indiana, United States

Site Status

Novartis Investigative Site

Kansas City, Kansas, United States

Site Status

Novartis Investigative Site

New Orleans, Louisiana, United States

Site Status

Novartis Investigative Site

New Orleans, Louisiana, United States

Site Status

Novartis Investigative Site

Detroit, Michigan, United States

Site Status

Novartis Investigative Site

Detroit, Michigan, United States

Site Status

Novartis Investigative Site

Jackson, Mississippi, United States

Site Status

Novartis Investigative Site

New York, New York, United States

Site Status

Novartis Investigative Site

Stony Brook, New York, United States

Site Status

Novartis Investigative Site

Cincinnati, Ohio, United States

Site Status

Novartis Investigative Site

Nashville, Tennessee, United States

Site Status

Novartis Investigative Site

Dallas, Texas, United States

Site Status

Novartis Investigative Site

Algiers, , Algeria

Site Status

Novartis Investigative Site

Algiers, , Algeria

Site Status

Novartis Investigative Site

Algiers, , Algeria

Site Status

Novartis Investigative Site

Oran, , Algeria

Site Status

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Site Status

Novartis Investigative Site

Buenos Aires, Buenos Aires F.D., Argentina

Site Status

Novartis Investigative Site

Coronel Suarez, Buenos Aires F.D., Argentina

Site Status

Novartis Investigative Site

Resistencia, Chaco Province, Argentina

Site Status

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Site Status

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Buenos Aires, , Argentina

Site Status

Novartis Investigative Site

Corrientes, , Argentina

Site Status

Novartis Investigative Site

Córdoba, , Argentina

Site Status

Novartis Investigative Site

Córdoba, , Argentina

Site Status

Novartis Investigative Site

Mendoza, , Argentina

Site Status

Novartis Investigative Site

Salta, , Argentina

Site Status

Novartis Investigative Site

Gosford, New South Wales, Australia

Site Status

Novartis Investigative Site

Auchenflower, Queensland, Australia

Site Status

Novartis Investigative Site

Greenslopes, Queensland, Australia

Site Status

Novartis Investigative Site

Bedford Park, , Australia

Site Status

Novartis Investigative Site

Eisenstadt, , Austria

Site Status

Novartis Investigative Site

Linz, , Austria

Site Status

Novartis Investigative Site

Mödling, , Austria

Site Status

Novartis Investigative Site

Vienna, , Austria

Site Status

Novartis Investigative Site

Vienna, , Austria

Site Status

Novartis Investigative Site

Fortaleza, Ceará, Brazil

Site Status

Novartis Investigative Site

Belo Horizonte, Minas Gerais, Brazil

Site Status

Novartis Investigative Site

Curitiba, Paraná, Brazil

Site Status

Novartis Investigative Site

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status

Novartis Investigative Site

Campinas, São Paulo, Brazil

Site Status

Novartis Investigative Site

Tatuí, São Paulo, Brazil

Site Status

Novartis Investigative Site

Curitiba, , Brazil

Site Status

Novartis Investigative Site

Recife, , Brazil

Site Status

Novartis Investigative Site

Rio de Janeiro, , Brazil

Site Status

Novartis Investigative Site

Sao Jose Do Rico Preto, , Brazil

Site Status

Novartis Investigative Site

Pleven, , Bulgaria

Site Status

Novartis Investigative Site

Plovdiv, , Bulgaria

Site Status

Novartis Investigative Site

Sofia, , Bulgaria

Site Status

Novartis Investigative Site

Sofia, , Bulgaria

Site Status

Novartis Investigative Site

Sofia, , Bulgaria

Site Status

Novartis Investigative Site

Varna, , Bulgaria

Site Status

Novartis Investigative Site

Edmonton, Alberta, Canada

Site Status

Novartis Investigative Site

Vancouver, British Columbia, Canada

Site Status

Novartis Investigative Site

Halifax, Nova Scotia, Canada

Site Status

Novartis Investigative Site

Ottawa, Ontario, Canada

Site Status

Novartis Investigative Site

Sainte-Foy, Quebec, Canada

Site Status

Novartis Investigative Site

San Miguel, Santiago Metropolitan, Chile

Site Status

Novartis Investigative Site

Concepción, , Chile

Site Status

Novartis Investigative Site

Santiago, , Chile

Site Status

Novartis Investigative Site

Santiago, , Chile

Site Status

Novartis Investigative Site

Beijing, Beijing Municipality, China

Site Status

Novartis Investigative Site

Beijing, Beijing Municipality, China

Site Status

Novartis Investigative Site

Fuzhou, Fujian, China

Site Status

Novartis Investigative Site

Guangzhou, Guangdong, China

Site Status

Novartis Investigative Site

Shijiazhuang, Hebei, China

Site Status

Novartis Investigative Site

Wuhan, Hubei, China

Site Status

Novartis Investigative Site

Changsha, Hunan, China

Site Status

Novartis Investigative Site

Changsha, Hunan, China

Site Status

Novartis Investigative Site

Baotou, Inner Mongolia, China

Site Status

Novartis Investigative Site

Changchun, Jilin, China

Site Status

Novartis Investigative Site

Dalian, Liaoning, China

Site Status

Novartis Investigative Site

Beijing, , China

Site Status

Novartis Investigative Site

Beijing, , China

Site Status

Novartis Investigative Site

Beijing, , China

Site Status

Novartis Investigative Site

Beijing, , China

Site Status

Novartis Investigative Site

Beijing, , China

Site Status

Novartis Investigative Site

Guangzhou, , China

Site Status

Novartis Investigative Site

Hangzhou, , China

Site Status

Novartis Investigative Site

Jinan, , China

Site Status

Novartis Investigative Site

Luoyang, , China

Site Status

Novartis Investigative Site

Shanghai, , China

Site Status

Novartis Investigative Site

Taiyuan, , China

Site Status

Novartis Investigative Site

Ürümqi, , China

Site Status

Novartis Investigative Site

Ürümqi, , China

Site Status

Novartis Investigative Site

Wuhan, , China

Site Status

Novartis Investigative Site

Xiamen, , China

Site Status

Novartis Investigative Site

Yangzhou, , China

Site Status

Novartis Investigative Site

Zhengzhou, , China

Site Status

Novartis Investigative Site

Zhengzhou, , China

Site Status

Novartis Investigative Site

Medellín, Antioquia, Colombia

Site Status

Novartis Investigative Site

Medellín, Antioquia, Colombia

Site Status

Novartis Investigative Site

Barranquilla, Atlántico, Colombia

Site Status

Novartis Investigative Site

Bogotá, Cundinamarca, Colombia

Site Status

Novartis Investigative Site

Bucaramanga, Santander Department, Colombia

Site Status

Novartis Investigative Site

Armenia, , Colombia

Site Status

Novartis Investigative Site

Bogotá, , Colombia

Site Status

Novartis Investigative Site

Bogotá, , Colombia

Site Status

Novartis Investigative Site

Cali, , Colombia

Site Status

Novartis Investigative Site

Guayaquil, Guayas, Ecuador

Site Status

Novartis Investigative Site

Quito, Pichincha, Ecuador

Site Status

Novartis Investigative Site

Guayaquil, , Ecuador

Site Status

Novartis Investigative Site

Portoviejo, , Ecuador

Site Status

Novartis Investigative Site

Alexandria, , Egypt

Site Status

Novartis Investigative Site

Cairo, , Egypt

Site Status

Novartis Investigative Site

Cairo, , Egypt

Site Status

Novartis Investigative Site

El Menia, Upper Egypt, , Egypt

Site Status

Novartis Investigative Site

Suez Canal Region, , Egypt

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Bonn, , Germany

Site Status

Novartis Investigative Site

Essen, , Germany

Site Status

Novartis Investigative Site

Freiburg im Breisgau, , Germany

Site Status

Novartis Investigative Site

Göttingen, , Germany

Site Status

Novartis Investigative Site

Halle, , Germany

Site Status

Novartis Investigative Site

Hanover, , Germany

Site Status

Novartis Investigative Site

Heidelberg, , Germany

Site Status

Novartis Investigative Site

Homburg, , Germany

Site Status

Novartis Investigative Site

Ludwigshafen, , Germany

Site Status

Novartis Investigative Site

Lübeck, , Germany

Site Status

Novartis Investigative Site

Nuremberg, , Germany

Site Status

Novartis Investigative Site

Würzburg, , Germany

Site Status

Novartis Investigative Site

Athens, GR, Greece

Site Status

Novartis Investigative Site

Athens, GR, Greece

Site Status

Novartis Investigative Site

Athens, GR, Greece

Site Status

Novartis Investigative Site

Thessaloniki, GR, Greece

Site Status

Novartis Investigative Site

Athens, , Greece

Site Status

Novartis Investigative Site

Athens, , Greece

Site Status

Novartis Investigative Site

Athens, , Greece

Site Status

Novartis Investigative Site

Glyfada, , Greece

Site Status

Novartis Investigative Site

Ioannina, , Greece

Site Status

Novartis Investigative Site

Piraeus, , Greece

Site Status

Novartis Investigative Site

Thessaloniki, , Greece

Site Status

Novartis Investigative Site

Guatemala City, , Guatemala

Site Status

Novartis Investigative Site

Guatemala City, , Guatemala

Site Status

Novartis Investigative Site

Panjim, Goa, India

Site Status

Novartis Investigative Site

Ahmedabad, Gujarat, India

Site Status

Novartis Investigative Site

Vadodara, Gujarat, India

Site Status

Novartis Investigative Site

Gurgaon, Haryana, India

Site Status

Novartis Investigative Site

Bangalore, Karnataka, India

Site Status

Novartis Investigative Site

Bangalore, Karnataka, India

Site Status

Novartis Investigative Site

Manipal, Karnataka, India

Site Status

Novartis Investigative Site

Nagpur, Maharashtra, India

Site Status

Novartis Investigative Site

Pune, Maharashtra, India

Site Status

Novartis Investigative Site

Pune, Maharashtra, India

Site Status

Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, India

Site Status

Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, India

Site Status

Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, India

Site Status

Novartis Investigative Site

Amritsar, Punjab, India

Site Status

Novartis Investigative Site

Ludhiana, Punjab, India

Site Status

Novartis Investigative Site

Ludhiana, Punjab, India

Site Status

Novartis Investigative Site

Chennai, Tamil Nadu, India

Site Status

Novartis Investigative Site

Hyderabad, Telangana, India

Site Status

Novartis Investigative Site

Hyderabad, Telangana, India

Site Status

Novartis Investigative Site

Kolkata, West Bengal, India

Site Status

Novartis Investigative Site

Kolkata, West Bengal, India

Site Status

Novartis Investigative Site

India, , India

Site Status

Novartis Investigative Site

Mumbai, , India

Site Status

Novartis Investigative Site

New Delhi, , India

Site Status

Novartis Investigative Site

New Delhi, , India

Site Status

Novartis Investigative Site

Tangerang, Banten, Indonesia

Site Status

Novartis Investigative Site

East Jakarta, DKI Jakarta, Indonesia

Site Status

Novartis Investigative Site

South Jakarta, DKI Jakarta, Indonesia

Site Status

Novartis Investigative Site

West Jakarta, DKI Jakarta, Indonesia

Site Status

Novartis Investigative Site

Surabaya, East Java, Indonesia

Site Status

Novartis Investigative Site

Medan, North Sumatera, Indonesia

Site Status

Novartis Investigative Site

Bandung, West Java, Indonesia

Site Status

Novartis Investigative Site

Bekasi, West Java, Indonesia

Site Status

Novartis Investigative Site

Padang, West Sumatra, Indonesia

Site Status

Novartis Investigative Site

Jerusalem, , Israel

Site Status

Novartis Investigative Site

Jerusalem, , Israel

Site Status

Novartis Investigative Site

Kfar Saba, , Israel

Site Status

Novartis Investigative Site

Nazareth, , Israel

Site Status

Novartis Investigative Site

Sefad, , Israel

Site Status

Novartis Investigative Site

Kitakyushu, Fukuoka, Japan

Site Status

Novartis Investigative Site

Kure, Hiroshima, Japan

Site Status

Novartis Investigative Site

Sakaidechō, Kagawa-ken, Japan

Site Status

Novartis Investigative Site

Kita-ku, Okayama-ken, Japan

Site Status

Novartis Investigative Site

Hirakata, Osaka, Japan

Site Status

Novartis Investigative Site

Chiyoda-ku, Tokyo, Japan

Site Status

Novartis Investigative Site

Nagasaki, , Japan

Site Status

Novartis Investigative Site

Amman, , Jordan

Site Status

Novartis Investigative Site

Amman, , Jordan

Site Status

Novartis Investigative Site

Amman, , Jordan

Site Status

Novartis Investigative Site

Amman, , Jordan

Site Status

Novartis Investigative Site

Irbid, , Jordan

Site Status

Novartis Investigative Site

El Chouf, LBN, Lebanon

Site Status

Novartis Investigative Site

Beirut, , Lebanon

Site Status

Novartis Investigative Site

Beirut, , Lebanon

Site Status

Novartis Investigative Site

Beirut, , Lebanon

Site Status

Novartis Investigative Site

Byblos, , Lebanon

Site Status

Novartis Investigative Site

Saida, , Lebanon

Site Status

Novartis Investigative Site

Alor Star, Kedah, Malaysia

Site Status

Novartis Investigative Site

Kota Bharu, Kelantan, Malaysia

Site Status

Novartis Investigative Site

Pulau Pinang, Pulau Pinang, Malaysia

Site Status

Novartis Investigative Site

Johor Bahru, , Malaysia

Site Status

Novartis Investigative Site

Kuala Lumpur, , Malaysia

Site Status

Novartis Investigative Site

Mexico City, Mexico City, Mexico

Site Status

Novartis Investigative Site

Mexico City, Mexico City, Mexico

Site Status

Novartis Investigative Site

Mexico City, Mexico City, Mexico

Site Status

Novartis Investigative Site

Culiacán, Sinaloa SN, Mexico

Site Status

Novartis Investigative Site

Aguascalientes, , Mexico

Site Status

Novartis Investigative Site

San Luis Potosí City, , Mexico

Site Status

Novartis Investigative Site

San Luis Potosí City, , Mexico

Site Status

Novartis Investigative Site

Xalapa, , Mexico

Site Status

Novartis Investigative Site

Xalapa, , Mexico

Site Status

Novartis Investigative Site

Casablanca, , Morocco

Site Status

Novartis Investigative Site

Marrakesh, , Morocco

Site Status

Novartis Investigative Site

Rabat, , Morocco

Site Status

Novartis Investigative Site

Amsterdam, , Netherlands

Site Status

Novartis Investigative Site

Groningen, , Netherlands

Site Status

Novartis Investigative Site

Leiderdorp, , Netherlands

Site Status

Novartis Investigative Site

Sneek, , Netherlands

Site Status

Novartis Investigative Site

Venlo, , Netherlands

Site Status

Novartis Investigative Site

Zwolle, , Netherlands

Site Status

Novartis Investigative Site

Hønefoss, , Norway

Site Status

Novartis Investigative Site

Oslo, , Norway

Site Status

Novartis Investigative Site

Skien, , Norway

Site Status

Novartis Investigative Site

San Jose de David, Provincia de Panamá, Panama

Site Status

Novartis Investigative Site

Panama City, , Panama

Site Status

Novartis Investigative Site

Baguio City, Baguio, Philippines

Site Status

Novartis Investigative Site

Cagayan de Oro City, Cagayan Valley, Philippines

Site Status

Novartis Investigative Site

Cebu City, Cebu, Philippines

Site Status

Novartis Investigative Site

Davao City, Davao Region, Philippines

Site Status

Novartis Investigative Site

Quezon City, Manila, Philippines

Site Status

Novartis Investigative Site

Manila, National Capital Region, Philippines

Site Status

Novartis Investigative Site

Angeles City, Pampanga, Philippines

Site Status

Novartis Investigative Site

Cluj-Napoca, Napoca, Romania

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Buzău, , Romania

Site Status

Novartis Investigative Site

Cluj-Napoca, , Romania

Site Status

Novartis Investigative Site

Focşani, , Romania

Site Status

Novartis Investigative Site

Lasi, , Romania

Site Status

Novartis Investigative Site

Timișoara, , Romania

Site Status

Novartis Investigative Site

Kazan', , Russia

Site Status

Novartis Investigative Site

Kemerovo, , Russia

Site Status

Novartis Investigative Site

Krasnodar, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Moscow, , Russia

Site Status

Novartis Investigative Site

Novosibirsk, , Russia

Site Status

Novartis Investigative Site

Ryazan, , Russia

Site Status

Novartis Investigative Site

S-Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saint Petersburg, , Russia

Site Status

Novartis Investigative Site

Saratov, , Russia

Site Status

Novartis Investigative Site

Saratov, , Russia

Site Status

Novartis Investigative Site

Stavropol, , Russia

Site Status

Novartis Investigative Site

Tyumen, , Russia

Site Status

Novartis Investigative Site

Ulyanovsk, , Russia

Site Status

Novartis Investigative Site

Vladivostok, , Russia

Site Status

Novartis Investigative Site

Volgograd, , Russia

Site Status

Novartis Investigative Site

Al Ahsa, , Saudi Arabia

Site Status

Novartis Investigative Site

Dammam, , Saudi Arabia

Site Status

Novartis Investigative Site

Dammam, , Saudi Arabia

Site Status

Novartis Investigative Site

Khamis Mushait, , Saudi Arabia

Site Status

Novartis Investigative Site

Riyadh, , Saudi Arabia

Site Status

Novartis Investigative Site

Durban, KwaZulu-Natal, South Africa

Site Status

Novartis Investigative Site

Bloemfontein, , South Africa

Site Status

Novartis Investigative Site

Cape Town, , South Africa

Site Status

Novartis Investigative Site

Cape Town, , South Africa

Site Status

Novartis Investigative Site

Rivonia, , South Africa

Site Status

Novartis Investigative Site

Gyeonggi-do, Bucheon-si, South Korea

Site Status

Novartis Investigative Site

Wŏnju, Gangwon-do, South Korea

Site Status

Novartis Investigative Site

Daejeon, Korea, South Korea

Site Status

Novartis Investigative Site

Cheongju-si, North Chungcheong, South Korea

Site Status

Novartis Investigative Site

Busan, , South Korea

Site Status

Novartis Investigative Site

Incheon, , South Korea

Site Status

Novartis Investigative Site

Pusan, , South Korea

Site Status

Novartis Investigative Site

Seoul, , South Korea

Site Status

Novartis Investigative Site

Seoul, , South Korea

Site Status

Novartis Investigative Site

Suwon, , South Korea

Site Status

Novartis Investigative Site

Taegu, , South Korea

Site Status

Novartis Investigative Site

Mallorca, Balearic Islands, Spain

Site Status

Novartis Investigative Site

Barakaldo, Basque Country, Spain

Site Status

Novartis Investigative Site

Barcelona, Catalonia, Spain

Site Status

Novartis Investigative Site

Barcelona, Catalonia, Spain

Site Status

Novartis Investigative Site

Tarragona, Catalonia, Spain

Site Status

Novartis Investigative Site

Mérida, Extremadura, Spain

Site Status

Novartis Investigative Site

Las Palmas de Gran Canaria, Las Palmas de G.C, Spain

Site Status

Novartis Investigative Site

Majadahonda, Madrid, Spain

Site Status

Novartis Investigative Site

Alicante, Valencia, Spain

Site Status

Novartis Investigative Site

Barcelona, , Spain

Site Status

Novartis Investigative Site

Córdoba, , Spain

Site Status

Novartis Investigative Site

León, , Spain

Site Status

Novartis Investigative Site

Murcia, , Spain

Site Status

Novartis Investigative Site

Gothenburg, , Sweden

Site Status

Novartis Investigative Site

Helsingborg, , Sweden

Site Status

Novartis Investigative Site

Karlshamn, , Sweden

Site Status

Novartis Investigative Site

Linköping, , Sweden

Site Status

Novartis Investigative Site

Malmo, , Sweden

Site Status

Novartis Investigative Site

Trollhättan, , Sweden

Site Status

Novartis Investigative Site

Basel, , Switzerland

Site Status

Novartis Investigative Site

Bruderholz, , Switzerland

Site Status

Novartis Investigative Site

Zurich, , Switzerland

Site Status

Novartis Investigative Site

Linkou District, , Taiwan

Site Status

Novartis Investigative Site

Taichung, , Taiwan

Site Status

Novartis Investigative Site

Tainan City, , Taiwan

Site Status

Novartis Investigative Site

Taipei, , Taiwan

Site Status

Novartis Investigative Site

Taipei, , Taiwan

Site Status

Novartis Investigative Site

Taipei, , Taiwan

Site Status

Novartis Investigative Site

Muang, Muang, Thailand

Site Status

Novartis Investigative Site

Muang, Thailand, Thailand

Site Status

Novartis Investigative Site

Muang, Thailand, Thailand

Site Status

Novartis Investigative Site

Khon Kaen, THA, Thailand

Site Status

Novartis Investigative Site

Bangkok, , Thailand

Site Status

Novartis Investigative Site

Bangkok, , Thailand

Site Status

Novartis Investigative Site

Chiang Mai, , Thailand

Site Status

Novartis Investigative Site

Monastir, , Tunisia

Site Status

Novartis Investigative Site

Sousse, , Tunisia

Site Status

Novartis Investigative Site

Tunis, , Tunisia

Site Status

Novartis Investigative Site

Tunis, , Tunisia

Site Status

Novartis Investigative Site

Tunis, , Tunisia

Site Status

Novartis Investigative Site

Pendik / Istanbul, Turkey, Turkey (Türkiye)

Site Status

Novartis Investigative Site

Ankara, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Ankara, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Bursa, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Bursa, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Diskapi / Ankara, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Haydarpasa/Istanbul, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Istanbul, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Meselik / Eskisehir, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Sivas, , Turkey (Türkiye)

Site Status

Novartis Investigative Site

Abu Dhabi, , United Arab Emirates

Site Status

Novartis Investigative Site

Al Ain City, , United Arab Emirates

Site Status

Novartis Investigative Site

Dubai, , United Arab Emirates

Site Status

Novartis Investigative Site

Dubai, , United Arab Emirates

Site Status

Novartis Investigative Site

Edgbaston, Birmingham, United Kingdom

Site Status

Novartis Investigative Site

Stockton-on-Tees, Cleveland, United Kingdom

Site Status

Novartis Investigative Site

Bradford, West Yorkshire, United Kingdom

Site Status

Novartis Investigative Site

Chesterfield, Yorkshire, United Kingdom

Site Status

Novartis Investigative Site

Herts, Yorkshire, United Kingdom

Site Status

Novartis Investigative Site

Chesterfield, , United Kingdom

Site Status

Novartis Investigative Site

Telford, , United Kingdom

Site Status

Novartis Investigative Site

Uxbridge, , United Kingdom

Site Status

Novartis Investigative Site

Wakefield, , United Kingdom

Site Status

Novartis Investigative Site

York, , United Kingdom

Site Status

Novartis Investigative Site

Ho Chi Minh City, , Vietnam

Site Status

Novartis Investigative Site

Ho Chi Minh City, , Vietnam

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Algeria Argentina Australia Austria Brazil Bulgaria Canada Chile China Colombia Ecuador Egypt Germany Greece Guatemala India Indonesia Israel Japan Jordan Lebanon Malaysia Mexico Morocco Netherlands Norway Panama Philippines Romania Russia Saudi Arabia South Africa South Korea Spain Sweden Switzerland Taiwan Thailand Tunisia Turkey (Türkiye) United Arab Emirates United Kingdom Vietnam

References

Explore related publications, articles, or registry entries linked to this study.

Filippatos G, Khan SS, Ambrosy AP, Cleland JG, Collins SP, Lam CS, Angermann CE, Ertl G, Dahlstrom U, Hu D, Dickstein K, Perrone SV, Ghadanfar M, Bermann G, Noe A, Schweizer A, Maier T, Gheorghiade M. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015 May;17(5):527-33. doi: 10.1002/ejhf.262. Epub 2015 Mar 10.

Reference Type BACKGROUND
PMID: 25754836 (View on PubMed)

Tay WT, Teng TK, Ouwerkerk W, Cleland JGF, Collins SP, Angermann CE, Dickstein K, Dahlstrom U, Schweizer A, Obergfell A, Yiu KH, Ghadanfar M, Hassanein M, Ren QW, Gu WL, Ertl G, Perrone SV, Filippatos G, Lam CSP, Tromp J. Global patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT-HF registry. Eur J Heart Fail. 2025 Oct 1. doi: 10.1002/ejhf.70056. Online ahead of print.

Reference Type DERIVED
PMID: 41031485 (View on PubMed)

Chyou JY, Tay WT, Tromp J, Ouwerkerk W, Yiu KH, Cleland JGF, Collins SP, Angermann CE, Ertl G, Dahlstrom U, Dickstein K, Perrone SV, Ghadanfar M, Schweizer A, Obergfell A, Filippatos G, Lam CSP. Prognostic Implications and Global Perspectives of Atrial Fibrillation in Patients Hospitalized for Heart Failure. JACC Heart Fail. 2025 Mar;13(3):453-464. doi: 10.1016/j.jchf.2024.11.009. Epub 2025 Feb 5.

Reference Type DERIVED
PMID: 39918534 (View on PubMed)

Ouwerkerk W, Tromp J, Cleland JGF, Angermann CE, Dahlstrom U, Ertl G, Hassanein M, Perrone SV, Ghadanfar M, Schweizer A, Obergfell A, Dickstein K, Filippatos G, Collins SP, Lam CSP. Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF. Eur J Heart Fail. 2023 Jan;25(1):43-51. doi: 10.1002/ejhf.2708. Epub 2022 Nov 23.

Reference Type DERIVED
PMID: 36196060 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRPORTHF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The FOCUS-ADHF Registry
NCT06726109 RECRUITING
Heart Failure Registry
NCT00530426 COMPLETED
Heart Failure Evaluation Study
NCT05583513 COMPLETED